New Jardiance (Empagliflozin) an oral diabetic drug showed reduced risk of cardiovascular events in patients with type 2 diabetes. The drug is an oral highly selective sodium glucose co-transporter (SGLT-2) inhibitor which acts by blocking the reabsorption of glucose in the kidney thereby lowering the blood glucose levels. It is approved to be used for the treatment of type 2 diabetes in adults.
Boehringer Ingelheim and Eli Lilly, two of the world's leading pharmaceutical companies continuously strive to focus on the patient's need in the treatment of diabetes. Diabetes is a chronic condition which is either due to the body's inability to synthesize normal insulin or the inefficiency to use the synthesized insulin hormone. Diabetes continues to increase the risk of high blood pressure, obesity and cardiovascular diseases.
‘New Jardiance (Empagliflozin) an oral diabetic medication lowered the risk of cardiovascular deaths in type 2 diabetic patients. The results of the EMPA-REG outcome trial were presented in the American Diabetes Association (ADA) 76th Scientific Sessions in New Orleans.’
AdvertisementThe EMPA-REG outcome trial established cardiovascular diseases among diabetes people. It was performed on more than 7000 patients from 42 countries all over the world. The study was also done to assess the effect of Jardiance in reducing the risk of cardiovascular diseases. It was found that the risk of cardiovascular death was reduced by 38% and the safety profile of the drug was consistent compared to the previous trials.
The results of the EMPA- REG outcome trial from Boehringer and Eli Lilly were presented in the American Diabetes Association (ADA) 76th Scientific Sessions in New Orleans. Reduced risk of cardiovascular diseases was seen in diabetic patients with Jardiance (empagliflozin) compared with placebo.
The data analysed the efficacy of the drug according to the patient's age. The participants of the trial were grouped under three categories as people below the age of 65, between 65-74 yrs and people above the age of 75 yrs. All three categories showed a reduced risk of heart failure and cardiovascular deaths. It was also found to be consistent with low density lipoprotein subgroups for the combination of cardiovascular death, non fatal heart attack or stroke.
Professor Hans-Juergen Woerle , Global Vice President Medicine of Boehringer Ingelheim stated that the analyzed results of EMPA-REG outcome trial reduced the risk of cardiovascular deaths and heart failure in type 2 diabetic patients. He also said that through continuous research the Diabetic Alliance between Boehringer Ingelheim and Eli Lilly and Company will continue to manage the risk of cardiovascular diseases in diabetic population.